← Back to All US Stocks

OmniAb, Inc. (OABIW) Stock Fundamental Analysis & AI Rating 2026

OABIW Nasdaq Services-Commercial Physical & Biological Research DE CIK: 0001846253
Recently Updated • Analysis: Apr 13, 2026 • SEC Data: 2025-12-31
STRONG SELL
85% Conf
Pending
Analysis scheduled

📊 OABIW Key Takeaways

Revenue: $18.7M
Net Margin: -347.0%
Free Cash Flow: $-37.0M
Current Ratio: 4.02x
Debt/Equity: 0.00x
EPS: $-0.57
AI Rating: STRONG SELL with 85% confidence
OmniAb, Inc. (OABIW) receives a STRONG SELL rating with 85% confidence from our AI fundamental analysis based on SEC 10-K filings. With revenue of $18.7M, net profit margin of -347.0%, and return on equity (ROE) of -24.3%, OmniAb, Inc. demonstrates mixed fundamentals in the Healthcare sector. Below is our complete OABIW stock analysis for 2026.

Is OmniAb, Inc. (OABIW) a Good Investment?

Claude

OmniAb is burning cash at an unsustainable rate (-$36.5M operating CF) while revenue contracts 29.3% YoY, generating massive operating losses (-369.5% margin). Despite a fortress balance sheet, the company's core business model is fundamentally broken with negative cash flow and deteriorating top-line growth indicating imminent financial distress.

Why Buy OmniAb, Inc. Stock? OABIW Key Strengths

Claude
  • + Strong balance sheet with zero long-term debt (Debt/Equity 0.00x)
  • + Excellent liquidity position with 4.02x current ratio and $25.5M cash
  • + Substantial stockholders' equity of $267.0M provides solvency buffer

OABIW Stock Risks: OmniAb, Inc. Investment Risks

Claude
  • ! Revenue declining 29.3% YoY with only $18.7M top-line
  • ! Operating cash flow negative at -$36.5M indicating business is destroying value
  • ! Extreme operating margin of -369.5% and net margin of -347.0% unsustainable
  • ! At current burn rate, cash runway limited to <9 months
  • ! Operating losses of $69.0M dwarf revenue, suggesting fundamental business model failure

Key Metrics to Watch

Claude
  • * Operating cash flow trend and cash runway remaining
  • * Revenue stabilization or continued decline
  • * Path to profitability and cost restructuring measures
  • * Quarterly cash burn rate and balance sheet depletion

OmniAb, Inc. (OABIW) Financial Metrics & Key Ratios

Revenue
$18.7M
Net Income
$-64.8M
EPS (Diluted)
$-0.57
Free Cash Flow
$-37.0M
Total Assets
$300.9M
Cash Position
$25.5M

💡 AI Analyst Insight

Strong liquidity with a 4.02x current ratio provides a solid financial cushion.

OABIW Profit Margin, ROE & Profitability Analysis

Gross Margin N/A
Operating Margin -369.5%
Net Margin -347.0%
ROE -24.3%
ROA -21.5%
FCF Margin -198.3%

OABIW vs Healthcare Sector: How OmniAb, Inc. Compares

How OmniAb, Inc. compares to Healthcare sector averages

Net Margin
OABIW -347.0%
vs
Sector Avg 12.0%
OABIW Sector
ROE
OABIW -24.3%
vs
Sector Avg 15.0%
OABIW Sector
Current Ratio
OABIW 4.0x
vs
Sector Avg 2.0x
OABIW Sector
Debt/Equity
OABIW 0.0x
vs
Sector Avg 0.6x
OABIW Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is OmniAb, Inc. Stock Overvalued? OABIW Valuation Analysis 2026

Based on fundamental analysis, OmniAb, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.

Return on Equity
-24.3%
Sector avg: 15%
Net Profit Margin
-347.0%
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
0.00x
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

OmniAb, Inc. Balance Sheet: OABIW Debt, Cash & Liquidity

Current Ratio
4.02x
Quick Ratio
3.97x
Debt/Equity
0.00x
Debt/Assets
11.3%
Interest Coverage
N/A
Long-term Debt
N/A

OABIW Revenue & Earnings Growth: 5-Year Financial Trend

OABIW 5-year financial data: Year 2022: Revenue $59.1M, Net Income -$27.0M, EPS $-0.33. Year 2023: Revenue $59.1M, Net Income -$22.3M, EPS $-0.26. Year 2024: Revenue $34.2M, Net Income -$50.6M, EPS $-0.51. Year 2025: Revenue $26.4M, Net Income -$62.0M, EPS $-0.61.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: OmniAb, Inc.'s revenue has declined by 55% over the 5-year period, indicating business contraction. The most recent EPS of $-0.61 indicates the company is currently unprofitable.

OABIW Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
-198.3%
Free cash flow / Revenue

OABIW Quarterly Earnings & Performance

Quarterly financial performance data for OmniAb, Inc. including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q3 2025 $2.2M -$13.6M $-0.14
Q2 2025 $3.9M -$13.6M $-0.13
Q1 2025 $3.8M -$18.2M $-0.17
Q3 2024 $4.2M -$6.1M $-0.16
Q2 2024 $6.9M -$6.1M $-0.13
Q1 2024 $3.8M -$6.1M $-0.06
Q3 2023 $5.5M -$6.1M $-0.15
Q2 2023 $6.9M -$6.1M $-0.12

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

OmniAb, Inc. Dividends, Buybacks & Capital Allocation

Operating Cash Flow
-$36.5M
Cash generated from operations
Capital Expenditures
$565.0K
Investment in assets
Dividends
None
No dividend program

OABIW SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for OmniAb, Inc. (CIK: 0001846253)

📋 Recent SEC Filings

Date Form Document Action
Apr 7, 2026 4 xslF345X06/wk-form4_1775607981.xml View →
Apr 7, 2026 4 xslF345X06/wk-form4_1775607900.xml View →
Apr 7, 2026 4 xslF345X06/wk-form4_1775607819.xml View →
Mar 4, 2026 10-K ck0001846253-20251231.htm View →
Mar 4, 2026 8-K oabi-20260304.htm View →

Frequently Asked Questions about OABIW

What is the AI rating for OABIW?

OmniAb, Inc. (OABIW) has an AI rating of STRONG SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.

What are OABIW's key strengths?

Claude: Strong balance sheet with zero long-term debt (Debt/Equity 0.00x). Excellent liquidity position with 4.02x current ratio and $25.5M cash.

What are the risks of investing in OABIW?

Claude: Revenue declining 29.3% YoY with only $18.7M top-line. Operating cash flow negative at -$36.5M indicating business is destroying value.

What is OABIW's revenue and growth?

OmniAb, Inc. reported revenue of $18.7M.

Does OABIW pay dividends?

OmniAb, Inc. does not currently pay dividends.

Where can I find OABIW SEC filings?

Official SEC filings for OmniAb, Inc. (CIK: 0001846253) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is OABIW's EPS?

OmniAb, Inc. has a diluted EPS of $-0.57.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Is OABIW a good stock to buy right now?

Based on our AI fundamental analysis in April 2026, OmniAb, Inc. has a STRONG SELL rating with 85% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.

Is OABIW stock overvalued or undervalued?

Valuation metrics for OABIW: ROE of -24.3% (sector avg: 15%), net margin of -347.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

Should I buy OABIW stock in 2026?

Our dual AI analysis gives OmniAb, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is OABIW's free cash flow?

OmniAb, Inc.'s operating cash flow is $-36.5M, with capital expenditures of $565.0K. FCF margin is -198.3%.

How does OABIW compare to other Healthcare stocks?

Vs Healthcare sector averages: Net margin -347.0% (avg: 12%), ROE -24.3% (avg: 15%), current ratio 4.02 (avg: 2).

Top Rated Stocks
NSSC 92% MLI 92% MELI 92% MDXG 92% MANH 92% INVA 92% GGG 92% GCT 92% FTNT 92% FSLR 92%
Sector: All Healthcare Stocks →
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Apr 13, 2026 | Data as of: 2025-12-31 | Powered by Claude AI